Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD1940 · 2 trials · 2 indications
Area under the Visual Analogue Scale (VAS, 0-100 mm) time curve 0-8h (from end of surgery). Missing values in the pain-by-time curve was imputated using linear interpolation, last observation carried forward (LOCF) or first observation carried backwards (FOCB) as applicable.
| Arm | Type | Description |
|---|---|---|
| AZD1940 | EXPERIMENTAL | AZD1940 800ug given predose |
| Naproxen | ACTIVE_COMPARATOR | Naproxen 500mg given pre-surgery |
| Placebo | PLACEBO_COMPARATOR | Placebo given pre-surgery |
| 1 | EXPERIMENTAL | AZD1940 + Placebo |
| 2 | OTHER | - |
| Name | Type | Description |
|---|---|---|
| AZD1940 | DRUG | 800ug oral administration |
| Naproxen | DRUG | 500mg oral administration |
| Placebo | DRUG | Placebo given pre-surgery |
| Midazolam | DRUG | Oral solution given orally once daily on day -1 and day 14 |
Inclusion Criteria: * Patients scheduled for surgical removal of one partial or complete impacted mandibular third molar. * Provision of signed informed consent. * Healthy males or non-fertile females. Exclusion Criteria: * History of somatic disease/condition, which may interfere with the object...
AZD1940 is an investigational small molecule being developed for pain, including low back pain. It has been studied in clinical trials for its analgesic efficacy and safety in patients with pain conditions. The drug is still in clinical development and is not approved for commercial use.
AZD1940 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca has conducted clinical trials to evaluate the drug's safety, tolerability, and efficacy in treating pain.
AZD1940 is in Phase 1 of clinical development. It has completed early-stage trials, including a Phase 1 study and a Phase 2 study, both of which are finished. The drug remains investigational and has not received regulatory approval.
AZD1940 has been studied in two completed clinical trials. NCT00659490 investigated the analgesic efficacy of a single dose in 151 participants with pain, and NCT00689780 examined safety, tolerability, and pharmacokinetics in 60 participants with low back pain. Both trials are completed.
AZD1940 is a distinct investigational compound developed by AstraZeneca. No alternative names for this drug have been disclosed in the clinical trial records. It is being studied specifically for its potential role in pain management.